北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (6): 951-957. doi: 10.3969/j.issn.1671-167X.2016.06.006

• 论著 • 上一篇    下一篇

类风湿关节炎患者外周血滤泡辅助性T细胞水平检测

安乐美,李娟,季兰岚,李光韬,张卓莉△   

  1. (北京大学第一医院风湿免疫科, 北京100034)
  • 出版日期:2016-12-18 发布日期:2016-12-18
  • 通讯作者: 张卓莉 E-mail:zhuoli.zhang@126.com
  • 基金资助:

    国家重点基础研究发展计划(973计划,2010CB529103)资助

Detection of peripheral follicular helper T cells in rheumatoid arthritis

AN Le-mei, LI Juan, JI Lan-lan, LI Guang-tao, ZHANG Zhuo-li△   

  1. (Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China)
  • Online:2016-12-18 Published:2016-12-18
  • Contact: ZHANG Zhuo-li E-mail:zhuoli.zhang@126.com
  • Supported by:

    Supported by the Major State Basic Research Development Program of People’s Republic of China (973 Program, 2010CB529103)

摘要:

目的:检测外周血滤泡辅助性T细胞(follicular T helper cells , Tfh cells)的比例及其表面标志,分析与类风湿关节炎(rheumatoid arthritis , RA)患者疾病活动度的关系。方法: 收集40例类风湿关节炎患者及20例正常对照组的外周血,分离外周血单个核细胞(peripheral blood mononuclear cells,  PBMC)及血清,流式细胞术检测PBMC中CD4+CXCR5+Tfh细胞(CXCR5, 趋化因子受体, C-X-C chemokine receptor type 5)的比例及其表面程序性细胞死亡1(programmed death-1, PD-1)、可诱导的协同刺激性因子(inducible co-stimulator, ICOS)、CD40配体(CD40 ligand, CD40L)及白介素21受体(interleukin-21  receptor, IL-21R)的表达情况,实时荧光定量PCR方法检测B 细胞淋巴瘤-6(B-cell lymphoma 6, Bcl-6)、白介素-21(interleukin-21, IL-21)及IL-21R的表达,酶联免疫吸附法(enzyme-linked immunosorbent assay , ELISA)检测血清中IL-21和B 细胞趋化因子CXC配体13 (B cell-attracting chemokine CXC ligand 13, CXCL13)水平。结果: (1)流式细胞术结果提示,与正常对照组比较,RA患者组外周血CXCR5+ CD4+Tfh细胞表达与正常对照组相比明显升高(16.75±3.92  vs. 7.49±1.84,P<0.001);低疾病活动度或缓解组RA外周血CXCR5+ CD4+Tfh细胞表达与正常对照组相比明显升高(16.62±3.43 vs. 7.49±1.84,P<0.001);中疾病活动度组RA外周血CXCR5+ CD4+Tfh细胞表达与正常对照组相比明显升高(16.82±3.07 vs. 7.49±1.84, P<0.001);高疾病活动度组RA外周血CXCR5+ CD4+Tfh细胞表达与正常对照组相比明显升高(16.87±5.50 vs. 7.49±1.84, P<0.001);RA患者外周血ICOS、PD-1、IL-21R在CD4+CXCR5+细胞的表达与正常对照组相比显著升高 (ICOS+ CXCR5+CD4+细胞, 8.37±4.28 vs. 3.72±1.81, P<0.001; PD-1+ CXCR5+CD4+细胞, 1.57±1.10 vs. 0.24±0.30, P=0.035; IL-21R+ CXCR5+CD4+细胞, 4.60±4.05 vs. 0.20±0.19, P=0.006),而CD40L在CD4+CXCR5+细胞的表达在两组间差异无统计学意义(3.38±3.71 vs. 0.54±0.34, P=0.135)。(2)RA患者组较正常对照组外周血中IL-21R mRNA升高(5.00±4.94 vs. 0.74±0.55, P<0.001),而转录因子Bcl-6 mRNA [4.54(3.33, 7.23) vs. 5.31(2.81, 7.44), P=0.329]以及IL-21 mRNA [0.72(0.26, 3.45) vs. 0.56(0.27, 3.71) P=0.195]表达差异无统计学意义(P>0.05);Bcl-6、IL-21和IL-21R mRNA的表达在不同组RA患者之间差异也无统计学意义(P>0.05)。(3)RA患者血清中IL-21、CXCL13水平明显高于正常对照组[IL-21, (200.49±154.56) ng/L vs. (8.21±5.95) ng/L, P<0.001; CXCL13, (43.09±1.28)ng/L vs. (93.72±49.72) ng/L,P<0.001];相关分析显示IL-21、CXCL13浓度与RA疾病活动度正相关(r>0.4),而血清类风湿因子(rheumatoid factor, RF)和抗环瓜氨酸多肽抗体(anti-citrullinated protein antibody, anti-CCP)与RA疾病活动度无相关性(r<0.2)。结论: 外周血Tfh细胞及其相关细胞因子在RA患者中显著升高,说明Tfh细胞可能参与RA的发病机制,阻断Tfh细胞的产生,有望成为治疗RA患者的新的作用靶点。

关键词: 关节炎, 类风湿, T淋巴细胞, 辅助诱导, 细胞因子类, 受体, CXCR5, 白细胞介素21

Abstract:

Objective: To detect cell frequency and surface markers of peripheral CD4+CXCR5+ follicular helper T (Tfh) cells and analyze the correlation between CD4+CXCR5+Tfh cells and rheumatoid arthritis (RA) disease activity. Methods: Forty RA patients meeting the American College of Rheumatology classification criteria for RA and twenty healthy controls (HC) were included. The peripheral blood mononuclear cells and sera were collected. The expressions of CD4+CXCR5+Tfh cells (CXCR5, C-X-C chemokine receptor type 5) and inducible T cell costimulator (ICOS), programmed death 1 positive (PD-1), interleukin-21 receptor (IL-21R) and CD40 ligand (CD40L) positive on CD4+CXCR5+Tfh cells were analyzed by flow cytometry. The transcript levels of B-cell lymphoma 6 (Bcl-6), as well as IL-21 and IL-21R, were measured by real-time polymerase chain reaction. Besides, serum IL-21 and CXCL13 concentrations were determined by enzyme-linked immunosorbent assay. The potential association between Tfh cells and RA disease activity was detected. Results: The cell surface marker of CXCR5+ on CD4+ cells was significantly increasingly higher across the following groups versus HC: total RA patients (16.75±3.92 vs.7.49±1.84, P<0.001); RA patients with low disease activity or remission (16.62±3.43 vs. 7.49±1.84, P<0.001); RA patients with moderate disease activity (16.82±3.07 vs. 7.49±1.84, P<0.001) and RA patients with high disease activity (16.87±5.50 vs. 7.49±1.84, P<0.001). Besides, the percentages of ICOS+, PD-1+, IL-21R+ on CD4+CXCR5+Tfh cells in the RA patients were significantly higher than that of HC (ICOS+CD4+CXCR5+cells, 8.37±4.28 vs. 3.72±1.81, P<0.001; PD-1+CD4+CXCR5+cells, 1.57±1.10 vs. 0.24±0.30, P=0.035; IL-21R+CD4+CXCR5+cells, 4.60±4.05 vs. 0.20±0.19, P=0.006). But the percentage of CD40L+ on CXCR5+CD4+Tfh cells in the RA patients was not significantly higher than that of HC (3.38±3.71 vs. 0.54±0.34, P=0.135). The IL-21R mRNA expression was elevated significantly (5.00±4.94 vs. 0.74±0.55, P<0.001) in the RA patients but not in Bcl-6 mRNA[4.54(3.33, 7.23) vs. 5.31(2.81, 7.44), P=0.329]or IL-21 mRAN[0.72(0.26, 3.45) vs. 0.56(0.27, 3.71), P=0.195]. Additionally, the serum interleukin-21 (IL-21)and CXCL13 levels in the RA patients were higher than in the healthy controls [IL-21, (200.49±154.56) ng/L vs. (8.21±5.95) ng/L, P<0.001; CXCL13, (93.72±49.72) ng/L vs. (43.09±1.28) ng/L, P<0.001] and were both positively correlated with RA disease activity indexes, including erythrocyte sedimentation rate, the disease activity score in 28 joints (ESR-based or CRP-based), clinical disease activity index, and simplified disease activity index. However, none of the Tfh cells, anti-citrullinated protein antibody or rheumatoid factor had any relationship with RA disease activity. Conclusion: Peripheral Tfh cells and their relevant cytokines are higher in RA patients than healthy controls, indicating Tfh cells may participate in the pathogenesis of RA, therefore, blocking the pathway of Tfh cells may be reasonable cellular targets for therapeutic intervention.

Key words: Arthritis, rheumatoid, T-lymphocytes, helper-inducer, Cytokines, Receptors, CXCR5,  , Interleukin-21

中图分类号: 

  • R593.22
[1] 汤莹, 张湧波, 吴丹红, 林炎鸿, 兰风华. 13例先天性双侧输精管缺如不育患者的致病基因突变检测[J]. 北京大学学报(医学版), 2024, 56(5): 763-774.
[2] 刘东武, 陈杰, 高明利, 于静. 类风湿关节炎伴发淋巴结Castleman样病理改变1例[J]. 北京大学学报(医学版), 2024, 56(5): 928-931.
[3] 李正芳,罗采南,武丽君,吴雪,孟新艳,陈晓梅,石亚妹,钟岩. 抗氨基甲酰化蛋白抗体在诊断类风湿关节炎中的应用价值[J]. 北京大学学报(医学版), 2024, 56(4): 729-734.
[4] 柴晓东,孙子文,李海爽,朱靓怡,刘小旦,刘延涛,裴斐,常青. 髓母细胞瘤分子亚型中CD8+T淋巴细胞浸润的临床病理特点[J]. 北京大学学报(医学版), 2024, 56(3): 512-518.
[5] 黄会娜,赵静,赵祥格,白自然,李霞,王冠. 乳酸对类风湿关节炎患者外周血CD4+T细胞亚群的调控作用[J]. 北京大学学报(医学版), 2024, 56(3): 519-525.
[6] 汤晓菲,李永红,丁秋玲,孙卓,张阳,王育梅,田美伊,刘坚. 类风湿关节炎患者下肢深静脉血栓发病率及危险因素[J]. 北京大学学报(医学版), 2024, 56(2): 279-283.
[7] 李红光,韩玮华,吴训,冯继玲,李刚,孟娟红. 关节腔冲洗联合液态浓缩生长因子注射治疗单侧颞下颌关节骨关节炎的初步研究[J]. 北京大学学报(医学版), 2024, 56(2): 338-344.
[8] 邹雪,白小娟,张丽卿. 艾拉莫德联合托法替布治疗难治性中重度类风湿关节炎的疗效[J]. 北京大学学报(医学版), 2023, 55(6): 1013-1021.
[9] 扶琼,叶霜. 嵌合抗原受体T细胞治疗在自身免疫疾病中的应用和思考[J]. 北京大学学报(医学版), 2023, 55(6): 953-957.
[10] 吴琦,蔡月明,何娟,黄文蒂,王庆文. 血脂异常与类风湿关节炎肺间质病变的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 982-992.
[11] 张警丰,金银姬,魏慧,姚中强,赵金霞. 体重指数与类风湿关节炎临床特征的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 993-999.
[12] 金银姬,孙琳,赵金霞,刘湘源. 血清IgA型抗鼠科肉瘤病毒癌基因同源物B1抗体在类风湿关节炎中的意义[J]. 北京大学学报(医学版), 2023, 55(4): 631-635.
[13] 朱晓娟,张虹,张爽,李东,李鑫,徐玲,李挺. 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报(医学版), 2023, 55(2): 243-253.
[14] 蔡文心,李仕成,刘一鸣,梁如玉,李静,郭建萍,胡凡磊,孙晓麟,李春,刘栩,叶华,邓立宗,李茹,栗占国. 类风湿关节炎临床分层及其特征的横断面研究[J]. 北京大学学报(医学版), 2022, 54(6): 1068-1073.
[15] 程昉,杨邵英,房星星,王璇,赵福涛. CCL28-CCR10通路在类风湿关节炎单核细胞迁移中的作用[J]. 北京大学学报(医学版), 2022, 54(6): 1074-1078.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!